No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease

byZain Cheema

May 2, 2023

in StudyGraphics

Reading Time: 1 min read

Treatment with semaglutide in patients with obesity may be associated with weight loss

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Chronic Disease

An intradialytic exercise intervention did not improve dialysis adequacy

May 18, 2026

FDA-approved weight loss medications associated with weight loss at one year

Chronic Disease

A planetary health diet is associated with a lower risk of developing chronic kidney disease

February 3, 2026

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

Weekly Rewinds

2 Minute Medicine Rewind February 2, 2026

February 2, 2026

Variation noted across pre- and post-marketing studies for FDA approved devices

Pharma

Corstasis’ Enbumyst nasal spray approved for edema

September 18, 2025

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Optimal implementation of sodium-glucose cotransporter-2 inhibitors in US patients with heart failure estimated to cause a significant reduction in worsening heart failure events over 3 years

Initial thoracic endovascular aortic repair not associated with reduced mortality and morbidity compared to medical therapy for acute uncomplicated type B aortic dissection

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

2 Minute Medicine Rewind November 14, 2022

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports